Table 2.
Recent studies using immunotherapies to treat pediatric acute leukemia (ClinicalTrials.gov and Pubmed, accessed 12/31/2014)
| Class | Target | Name | Mechanism | Studies in pediatric acute leukemia |
|---|---|---|---|---|
| Cell therapy | CD19 | CD19CART cells | Genetic modified T cells expressing CD19 specific CAR | 67, 70-73, NCT02028455,NCT 01864889, NCT01853631, NCT01593696, NCT01683279, NCT00840853, NCT01195480, NCT01864889 |
| CD19 CAR EBV-CTL | Allogeneic EBV specific cytotoxic T-lymphocytes (CTL) genetically modified to express CD19 specific CAR | NCT01430390 | ||
| CD22 | CD22 CAR T cells | Genetic modified T cells expressing CD22 specific CAR | 74, NCT02315612 | |
| CD33 | CART-33 | Modified autologous or donor-derive T cells expressing CD33 specific CAR | NCT01864902 | |
| Antibody therapy | CD19/CD3 | Blinatumomab | Bispecific T cell engager Ab | 68, 75, NCT0210853, NCT02187354 |
| CD19 | SGN-CD19A | mAb conjugated with monomethyl auristatin F | NCT017860 | |
| SAR-3419 | mAb conjugated with tubulin inhibitor maytasine derivative | NCT01440179 (terminated by sponsor) | ||
| MOR00208 | Fc-Optimized mAb | NCT01685021 | ||
| CD20 | Rituximab | mAb | 76, NCT01700946, NCT02259348, NCT1595048, NC01429610 | |
| CD22 | Moxetumomab | mAb conjugated with pseudomonas exotoxin | NCT02227108, NCT00659425 | |
| Inotuzumab | mAb conjugated with calicheamicin | 77 | ||
| Epratuzumab | mAb | 78, NCT01279707, NCT00098839, NCT01802814 | ||
| CD19/CD22 | Combotox | Bispecific mAb conjugated with ricin A chain | 79NCT01408106 | |
| CD33 | Gemtuzumab | mAb conjugated with calicheamicin | 80-83, NCT02221310 | |
| CD45 | AHN-12 | mAb conjugated to the radioisotope yttrium 90 | ||
| CD52 | Alemtuzumab | mAb | 54, NCT00089349 (completed) |
CAR, chimeric antigen receptor; EBV, Epstein-Barr virus; mAb, monoclonal antibody